Tumor News and Research

RSS

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

Scientists sequence tumor genomes from 50 breast cancer patients

In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells.

4 Apr 2011

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Research offers first structural insights into 'client' protein shape in chaperone presence

In the constantly morphing field of protein structure, scientists at The Scripps Research Institute offer yet another surprise: a common "chaperone" protein in cells thought to help other proteins fold has been shown instead to loosen them.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

Breast cancer genome reveals potential therapeutic targets

Scientists have sequenced the entire genomes of tumors from 50 breast cancer patients and found more than 1,700 gene mutations, most of which were unique to individual patients. The researchers at Washington University in St. Louis and the Siteman Cancer Center suggest that this variability and uniqueness made it difficult to predict outcomes of the cases.

3 Apr 2011

Pfizer to present new investigational compounds data against cancer at AACR meeting

Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling; dual inhibition of PI3K/mTOR; and cancer stem cell-based targets.

2 Apr 2011

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts from the SuperGen PIM kinase inhibitor program. Poster presentations by SuperGen and collaborators will occur on April 3 and 5, 2011 at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

2 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions Biotechnology, Inc. announced today that it has exercised an option to license Irinophore C, a liposomal formulation of Irinotecan, from the BC Cancer Agency in British Columbia, Canada.

2 Apr 2011

Study: MicroRNA can predict risk of BM in lung cancer patients

Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis, according to a study published today by Scottsdale Healthcare and the Translational Genomics Research Institute.

1 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research taking place in Orlando, Florida April 2-6, 2011.

1 Apr 2011

Analysis of non-tumor tissue may be an effective option for diagnosis of prostate cancer

Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer - analyzing non-tumor tissue may be an effective option, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

1 Apr 2011

Tumor News and Research

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

Scientists identify new treatment target for squamous cell lung cancer

Scientists sequence tumor genomes from 50 breast cancer patients

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

Research offers first structural insights into 'client' protein shape in chaperone presence

Life Technologies launches new TaqMan Mutation Detection Assays

Breast cancer genome reveals potential therapeutic targets

Pfizer to present new investigational compounds data against cancer at AACR meeting

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Thalidomide provides new hope for patients with difficult to treat liver cancer

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

Rsearchers define new step that controls programmed cell death in cancer cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

Champions enters exclusive license agreement with BCCA for Irinophore C

Study: MicroRNA can predict risk of BM in lung cancer patients

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Analysis of non-tumor tissue may be an effective option for diagnosis of prostate cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News